Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Hi David- I was wondering if intravenous vitamin C will keep me in remission after the ASCT transplant which I made back in 2014 for a multiple myeloma diagnosis earlier that year.
Presently the levels of Lambda are again increasing beyond the normal but they are not skyrocketing ….they are high but doctor said we can wait more before we start some treatment …presently lambda is 110 (maximum normal is 27).
I was wondering if there is a way I can stop the lambda from increasing before the doctor puts me on some treatment.
My oncologist requested one more blood test after a month from now and if the lambda showed higher he will then start some treatment.
Do you think the vitamin C injection if I start them from now , will they help decrease my lambda levels ?? Pls let me know the soonest? Thanks- Peter
I must begin my reply by saying that a remission of your MM from an autologous stem cell transplant in 2014 until now is a darn good remission. A six plus year remission is well-beyond the average.
My guess is that if your lambda light chains are slowly increasing, you are experiencing a biochemical relapse. See the article linked below.
Do you have any CRAB symptoms? You didn’t mention any so I’m thinking that you don’t.
I am wondering about your slow relapse because you may want to consider a couple of different therapy paths.
To answer your question, yes, intravenous vitamin C therapy has been shown to kill MM cells.
Further, you may want to consider other types of non-toxic nutrition supplements, like IVC, that have beeshown to fight MM. I will link the MM CC supplements guide below.
Assuming that you and your oncologist agree to eventually begin chemotherapy again someday, consider low-dose chemotherapy such as low-dose revlimid (lenalidomide) or low-dose velcade (bortezomib).
Undergoing low dose chemo means less chemo, less toxicity to you. Both Revlimid and Velcade integrate with several non-toxic therapies.
For example, Revlimid integrates with curcumin and Velcade integrates also with curcumin but also integrates with CBD oil.
The long-term advantage to you is that research has shown that low-dose therapies are easier on you and may allow you to manage your MM for years to come. Please read the study linked below.
Let me know if you have any questions. Good luck.
“A biochemical relapse may require careful monthly monitoring of M-protein levels until significant progression occurs.
Treatment of biochemical relapse is indicated as follows: a doubling of serum M-protein, increase of serum M-protein by ≥10 g/L, increase of urine M-protein by ≥500 mg per 24 hours or an increase of involved serum-free light chains (FLC) level by ≥200 mg/L (plus abnormal ratio) by 2 measurements, 2 months apart. In high-risk patients, such as those with aggressive disease at diagnosis or a short treatment-free interval with a suboptimal response to previous treatment or imminent risk for organ dysfunction such as previous light chain-induced renal impairment or new bone lesions or adverse cytogenetics [t(4;14), del17p, or both], treatment should be initiated early after biochemical relapse is diagnosed to avoid serious symptomatic disease.3..”
“High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to toxicities to normal cells and there is a need to target only tumor cells and/or lower standard drug dosage without losing efficacy. We show that pharmacologically-dosed ascorbic acid (PAA), in the presence of iron, leads to the formation of highly reactive oxygen species (ROS) resulting in cell death.
PAA selectively kills CD138+MM tumor cells derived from MM and smoldering MM (SMM) but not from monoclonal gammopathy undetermined significance (MGUS) patients. PAA alone or in combination with melphalan inhibits tumor formation in MM xenograft mice. This study shows PAA efficacy on primary cancer cells and cell lines in vitro and in vivo.
Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model. Its effect on the other IMid, lenalidomide, has not been evaluated. This study aims to investigate the mechanism of action of curcumin and its potential ability to positively interact with lenalidomide.
Method: we designed an in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in combination with lenalidomide on the human myeloma H929 cell line.
Results: Incubation of H929 cells with curcumin (30mM) or lenalidomide (2.5 mM) for 3 days resulted in 26.35% (±1.06) and 30.81%(±2.98) apoptotic cells respectively. When 30 mM curcumin was combined with 2.5 mM lenalidomide, 50.4% (±3.37) apoptotic cells were detected by flow cytometry and the increase was significant compared to either curcumin alone or lenalidomide alone (anova p = 0.0026). Furthermore, gene analysis studies show that curcumin enhances the cytotoxic effect of lenalidomide via suppression of the cereblon and multi-drug resistant genes.
Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.